Brought to you by 
Celgene buys Receptos for $7.3bn cash
20 Aug 2020
Executive Summary
Celgene Corp. paid $232 per share in cash ($7.3bn, or $7.2bn net of cash acquired) to buy public immune and metabolic disease drug developer Receptos Inc. The price paid is a 21% premium to Receptos’ ten-day pre-announcement trading average.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene buys Receptos for $7.3bn cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice